DCC2036 (Rebastinib)
≥98%
- Product Code: 61767
CAS:
1020172-07-9
| Molecular Weight: | 553.59 g./mol | Molecular Formula: | C₃₀H₂₈FN₇O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
DCC2036, also known as Rebastinib, is primarily utilized in the field of oncology as a targeted therapy. It functions as a potent inhibitor of the TIE2 kinase receptor, which plays a crucial role in angiogenesis—the process of new blood vessel formation. By blocking TIE2, Rebastinib disrupts the signaling pathways that tumors rely on for growth and metastasis, particularly in cancers that are dependent on angiogenesis for their progression.
One of the key applications of Rebastinib is in the treatment of solid tumors, where it has shown promise in reducing tumor growth and preventing the spread of cancer cells. It is often explored in combination with other anticancer agents to enhance therapeutic efficacy. Additionally, Rebastinib is being investigated for its potential in overcoming resistance to other targeted therapies, making it a valuable candidate in the development of advanced cancer treatment regimens.
Clinical trials have also focused on its use in specific cancer types, such as breast cancer and glioblastoma, where TIE2 signaling is particularly active. By targeting this pathway, Rebastinib aims to improve patient outcomes and provide a more effective treatment option for those with limited alternatives. Its role in modulating the tumor microenvironment further highlights its potential in creating a less favorable condition for cancer cell survival and proliferation.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | €157.66 |
+
-
|
DCC2036 (Rebastinib)
DCC2036, also known as Rebastinib, is primarily utilized in the field of oncology as a targeted therapy. It functions as a potent inhibitor of the TIE2 kinase receptor, which plays a crucial role in angiogenesis—the process of new blood vessel formation. By blocking TIE2, Rebastinib disrupts the signaling pathways that tumors rely on for growth and metastasis, particularly in cancers that are dependent on angiogenesis for their progression.
One of the key applications of Rebastinib is in the treatment of solid tumors, where it has shown promise in reducing tumor growth and preventing the spread of cancer cells. It is often explored in combination with other anticancer agents to enhance therapeutic efficacy. Additionally, Rebastinib is being investigated for its potential in overcoming resistance to other targeted therapies, making it a valuable candidate in the development of advanced cancer treatment regimens.
Clinical trials have also focused on its use in specific cancer types, such as breast cancer and glioblastoma, where TIE2 signaling is particularly active. By targeting this pathway, Rebastinib aims to improve patient outcomes and provide a more effective treatment option for those with limited alternatives. Its role in modulating the tumor microenvironment further highlights its potential in creating a less favorable condition for cancer cell survival and proliferation.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :